Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? (2018)
Attributed to:
CANCER: Trials with potential global reach and other challenging trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/annonc/mdx715
PubMed Identifier: 29177440
Publication URI: http://europepmc.org/abstract/MED/29177440
Type: Journal Article/Review
Volume: 29
Parent Publication: Annals of oncology : official journal of the European Society for Medical Oncology
Issue: 2
ISSN: 0923-7534